Inflammatory Bowel Disease
IBD sgi Diagnostic has transitioned to IBD Precis®
IBD sgi Diagnostic was Prometheus Laboratories’ 4th-generation diagnostic test for inflammatory bowel disease (IBD) combining serologic, genetic and inflammation markers with a proprietary algorithm to help differentiate IBD from non-IBD and ulcerative colitis (UC) from Crohn’s disease (CD).
IBD sgi Diagnostic transitioned to IBD Precis on April 1, 2026, and can no longer be ordered.
IBD Precis builds upon the proven performance of previous diagnostic solutions and advances serologic testing by leveraging novel markers that not only aid in differentiating IBD from non-IBD and CD from UC but also help to risk stratify disease and non-invasively indicate potential colonic and/or ileal involvement.
IBD Precis marks the first time in 20 years that new serological markers have been incorporated into this technology – expanding clinical insights and improving the sensitivity and specificity, particularly for UC and colonic disease involvement.
IBD Precis is the start of the Prometheus continuum of care for IBD patients
IBD Precis and IBD sgi Diagnostic are laboratory-developed tests that were developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and are performed exclusively in our high complexity CLIA certified (05D0917432) and College of American Pathologists (CAP) accredited (6805501) clinical laboratory. As laboratory developed tests, they have not been cleared or approved by the US FDA. The test may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. Anser, IBD Precis, IBD sgi Diagnostic, PredictrPK, Prometheus and Respondr are trademarks of Prometheus Laboratories Inc. This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.